The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Antares Pharma met expectations on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue grew slightly. GAAP earnings per share.
Gross margins increased, operating margins dropped, net margins dropped.
Antares Pharma reported revenue of $5.5 million. The four analysts polled by S&P Capital IQ predicted a top line of $5.5 million on the same basis. GAAP reported sales were the same as the prior-year quarter's.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.04. The four earnings estimates compiled by S&P Capital IQ predicted -$0.03 per share. GAAP EPS were -$0.04 for Q4 versus $0.00 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 69.1%, 860 basis points better than the prior-year quarter. Operating margin was -91.7%, much worse than the prior-year quarter. Net margin was -91.1%, much worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $6.6 million. On the bottom line, the average EPS estimate is -$0.02.
Next year's average estimate for revenue is $35.6 million. The average EPS estimate is $0.00.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 183 members out of 201 rating the stock outperform, and 18 members rating it underperform. Among 24 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 19 give Antares Pharma a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Antares Pharma is buy, with an average price target of $5.25.
Looking for alternatives to Antares Pharma? It takes more than great companies to build a fortune for the future. Learn the basic financial habits of millionaires next door and get focused stock ideas in our free report, "3 Stocks That Will Help You Retire Rich." Click here for instant access to this free report.
- Add Antares Pharma to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why Antares Pharma Inc Plummeted Today
An FDA rejection is coming for the drugmaker's testosterone replacement therapy Xyosted.
Why Shares in Antares Pharma, Inc. Burst Today
Antares Pharma, Inc. shares tumbled after it priced its secondary stock offering.
3 Stocks Crushed by the Market This Week
Find out which health-care stocks got beaten down the most by the market over the past few days.